Independent guide
Semaglutide vs Tirzepatide
Both are used in prescription medicines, but their receptor activity, branded products, indications, evidence and access pathways differ.
Health information: This article is educational, not medical advice. FDA-approved branded medicines and compounded preparations are different regulatory categories. Treatment choice and prescribing require an appropriate clinician.
The key distinction
Semaglutide acts on GLP-1 receptors; tirzepatide acts on GIP and GLP-1 receptors.
A clinician should compare medical history, indication, contraindications, tolerability, access and other individual factors—not just average trial results.
Practical comparison
Compounded versions add a separate regulatory question because they are not FDA-approved.
Compare the exact product being offered, not ingredient names in isolation.
Sources
- HealthRX pricing
- HealthRX FAQ
- FDA: concerns with unapproved GLP-1 drugs
- FDA: 2026 compounding policy clarification
- FDA Wegovy prescribing information
- FDA Zepbound prescribing information
Provider prices and policies can change. We date-check unstable facts and distinguish provider claims from FDA or prescribing-information sources.